TriangleDISEASE & TREATMENT SETTING
Lifyorli: peritoneal cancer after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Broader topic: Malignant Peritoneal Neoplasm
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- who have received one to three prior systemic treatment regimens
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Lifyorli (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice